We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Tumor Boards
Colleague Insights
Living Resources
Conferences
Video Expert Opinion
Round Table Discussions
Sign in
Join now
featured
Published in Advanced Prostate Cancer

Expert Opinion / Cases · March 18, 2021

Systemic Treatment for Patient With Progressing mCRPC

Written by
Pedro C. Barata MD

 

 Save  Recommend
 Share

Discuss This item Follow

No comments yet, be the first to start the discussion!

  • Gregory Lewis

    Mar 19, 2021

    4 - pembrolizumab 
   In prostate cancer, CDK12 mutations occur in 5%−7% of patients with mCRPC, and most are biallelic inactivations.
   CDK12-altered/mutated prostate cancer is an aggressive subtype with poor responses and outcomes to hormonal, taxane, and PARP inhibitor therapies. A proportion of these patients may respond favorably to PD-1 inhibitors, which implicates CDK12 deficiency in immunotherapy sensitivity.

  • Juan Artigas

    Mar 19, 2021

    He should be treated with cabazitaxel and pembrolizumab. CDK12 does not respond to PARP inhibitors.

  • Bahram Mofid

    Mar 23, 2021

    He should be treared with pembrolizumab

  • Charles Maack

    May 07, 2021

    pembrolizumab as explained by Gregory Lewis

  • Noureddine Benjaafar

    Jun 12, 2021

    Pembroluzumab or cabazitaxel

  • silvia scalbi

    May 18, 2022

    cabazitaxel

  • Charles Maack

    May 19, 2022

    Will we ever be provided what subsequent protocol was followed or what the author was aware in advance when we participate in these questions for our opinion?

  • Jul 05, 2022

    Pending Moderator approval.
    Delete

Further Reading

Most Read This Week

Recently Updated